MRNA Moderna Inc

Price (delayed)

$106.56

Market cap

$40.71B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$12.33

Enterprise value

$39.02B

Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert ...

Highlights
The quick ratio has grown by 47% from the previous quarter and by 38% YoY
The equity is down by 28% YoY but it is up by 3% QoQ
The debt has grown by 21% year-on-year but it has declined by 4.2% since the previous quarter
The company's EPS has shrunk by 158% YoY and by 35% QoQ
The net income has plunged by 156% YoY and by 36% from the previous quarter

Key stats

What are the main financial stats of MRNA
Market
Shares outstanding
382.07M
Market cap
$40.71B
Enterprise value
$39.02B
Valuations
Price to book (P/B)
2.93
Price to sales (P/S)
5.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.7
Earnings
Revenue
$6.85B
EBIT
-$3.94B
EBITDA
-$3.32B
Free cash flow
-$3.83B
Per share
EPS
-$12.33
Free cash flow per share
-$10.01
Book value per share
$36.34
Revenue per share
$17.93
TBVPS
$48.24
Balance sheet
Total assets
$18.43B
Total liabilities
$4.57B
Debt
$1.22B
Equity
$13.85B
Working capital
$7.31B
Liquidity
Debt to equity
0.09
Current ratio
3.42
Quick ratio
3.15
Net debt/EBITDA
0.51
Margins
EBITDA margin
-48.5%
Gross margin
31.5%
Net margin
-68.8%
Operating margin
-61.9%
Efficiency
Return on assets
-22.5%
Return on equity
-29.9%
Return on invested capital
-25.8%
Return on capital employed
-25.6%
Return on sales
-57.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRNA stock price

How has the Moderna stock price performed over time
Intraday
-3.64%
1 week
2.37%
1 month
9.31%
1 year
-27.47%
YTD
7.15%
QTD
7.15%

Financial performance

How have Moderna's revenue and profit performed over time
Revenue
$6.85B
Gross profit
$2.16B
Operating income
-$4.24B
Net income
-$4.71B
Gross margin
31.5%
Net margin
-68.8%
The net income has plunged by 156% YoY and by 36% from the previous quarter
The operating income has plunged by 145% YoY and by 59% from the previous quarter
Moderna's operating margin has shrunk by 112% QoQ
MRNA's gross profit has plunged by 84% YoY and by 37% from the previous quarter

Growth

What is Moderna's growth rate over time

Valuation

What is Moderna stock price valuation
P/E
N/A
P/B
2.93
P/S
5.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.7
The company's EPS has shrunk by 158% YoY and by 35% QoQ
MRNA's P/B is 56% below its 5-year quarterly average of 6.7
The equity is down by 28% YoY but it is up by 3% QoQ
The stock's P/S is 88% below its 5-year quarterly average of 47.6 but 32% above its last 4 quarters average of 4.5
MRNA's revenue has dropped by 64% year-on-year and by 25% since the previous quarter

Efficiency

How efficient is Moderna business performance
Moderna's ROA has plunged by 171% YoY and by 48% from the previous quarter
MRNA's return on equity has dropped by 165% year-on-year and by 47% since the previous quarter
The ROIC has plunged by 145% YoY and by 80% from the previous quarter
The company's return on sales has shrunk by 123% QoQ

Dividends

What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRNA.

Financial health

How did Moderna financials performed over time
The quick ratio has grown by 47% from the previous quarter and by 38% YoY
The current ratio is up by 39% since the previous quarter and by 25% year-on-year
The debt is 91% smaller than the equity
The company's debt to equity has surged by 80% YoY
The equity is down by 28% YoY but it is up by 3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.